From genomic landscapes to personalized cancer management-is there a roadmap?

Annals of the New York Academy of Sciences

Volumn 1210, Issue 1, 2010, Pages 34-44

  Swanton, Charles ^a,b   Caldas, Carlos ^c,d  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

Author keywords

Cancer management; Clinical trial; Drug resistance; Predictive biomarker; Prognostic biomarker

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CARBOPLATIN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 10; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR BETA; FLUOROURACIL; GEFITINIB; GENOMIC RNA; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE B; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG; DNA; PROTEIN; TUMOR MARKER;

ARTICLE; BIOINFORMATICS; BREAST CANCER; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER GENETICS; CANCER PATIENT; CANCER THERAPY; CARCINOGENESIS; CLINICAL EVALUATION; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; DRUG EFFICACY; FUNCTIONAL GENOMICS; GENE DOSAGE; GENE OVEREXPRESSION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; LANDSCAPE; LUNG NON SMALL CELL CANCER; META ANALYSIS; MOLECULAR BIOLOGY; NEOPLASM; OVARY CANCER; PATIENT ASSESSMENT; PERSONALIZED MEDICINE; PREDICTIVE VALUE; PROSPECTIVE STUDY; PROSTATE CANCER; RISK ASSESSMENT; RISK FACTOR; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE; GENETIC MARKER; GENETICS; GENOMICS; HUMAN GENOME; METHODOLOGY; PATHOPHYSIOLOGY; PHARMACOGENETICS;

ANTINEOPLASTIC AGENTS; DNA; GENETIC MARKERS; GENOME, HUMAN; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS; PHARMACOGENETICS; PROTEINS; RNA INTERFERENCE; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 78349267957     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05776.x     Document Type: Article

References (51)

1. Swanton, C. & C. Caldas 2009. Molecular classification of solid tumors: towards pathway-driven therapeutics. Br. J. Cancer 100: 1517-1522.
2. Yap, T.A. et al 2010. Envisioning the future of early anticancer drug development. Nat. Rev. Cancer 10: 514-523.
3. Sikorski, R. & B. Yao 2010. Visualizing the landscape of selection biomarkers in current phase III oncology clinical trials. Sci. Transl. Med. 2: 34ps27.
4. Jemal, A., E. Ward, & M. Thun 2010. Declining death rates reflect progress against cancer. PLoS One 5: e9584.
5. Paik, S. et al 2004. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351: 2817-2826.
6. Paik, S. et al 2006. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 24: 3726-3734.
7. Leary, R.J. et al 2010. Development of personalized tumor biomarkers using massively parallel sequencing. Sci. Transl. Med. 2: 20ra14.
8. Van Cutsem, E. et al 2009. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J. Clin. Oncol. 27: 18s.
9. Heinrich, M.C. et al 2006. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J. Clin. Oncol. 24: 4764-4774.
10. Handolias, D., et al 2010. Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT. Br. J. Cancer 102: 1219-1223.
11. Downward, J. et al 1984. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 307: 521-527.
12. Downward, J., P. Parker, & M.D. Waterfield 1984. Autophosphorylation sites on the epidermal growth factor receptor. Nature 311: 483-485.
13. Kris, M.G. et al 2003. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290: 2149-2158.
14. Giaccone, G. et al 2004. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J. Clin. Oncol. 22: 777-784.
15. Lynch, T.J. et al 2004. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350: 2129-2139.
16. Mok, T.S. et al 2009. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361: 947-957.
17. Heidorn, S.J. et al 2010. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140: 209-221.
18. Ein-Dor, L., O. Zuk, & E. Domany 2006. Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc. Natl. Acad. Sci. USA 103: 5923-5928.
19. Ashworth, A. 2008. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J. Clin. Oncol. 26: 3785-3790.
20. Iorns, E. et al 2007. Utilizing RNA interference to enhance cancer drug discovery. Nat. Rev. Drug. Discov. 6: 556-568.
21. Swanton, C. et al 2008. Functional genomic analysis of drug sensitivity pathways to guide adjuvant strategies in breast cancer. Breast Cancer Res. 10: 214-221.
22. Berns, K. et al 2007. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12: 395-402.
23. Iorns, E. et al 2008. Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell 13: 91-104.
24. Swanton, C. et al 2007. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 11: 498-512.
25. Juul, N. et al 2010. Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. Lancet Oncol 11: 358-365.
26. Swanton, C. et al 2009. Chromosomal instability determines taxane response. Proc. Natl. Acad. Sci. USA 106: 8671-8676.
27. Amado, R.G. et al 2008. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26: 1626-1634.
28. Hayes, D.F. et al 2007. HER2 and response to paclitaxel in node-positive breast cancer. N. Engl. J. Med. 357: 1496-1506.
29. Takano, T. et al 2008. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. J. Clin. Oncol. 26: 5589-5595.
30. Mulligan, A.M. et al 2008. Prognostic effect of basal-like breast cancers is time dependent: evidence from tissue microarray studies on a lymph node-negative cohort. Clin. Cancer Res. 14: 4168-4174.
31. Blows, F.M. et al 2010. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10, 159 cases from 12 studies. PLoS Med. 7: e1000279.
32. Bartlett, J.M. et al 2010. Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncol. 11: 266-274.
33. Shah, S.P. et al 2009. Mutational evolution in a lobular breast tumor profiled at single nucleotide resolution. Nature 461: 809-813.
34. Stephens, P.J. et al 2009. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 462: 1005-1010.
35. Ding, L. et al 2010. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464: 999-1005.
36. Navin, N. et al 2010. Inferring tumor progression from genomic heterogeneity. Genome Res. 20: 68-80.
37. 2010. Editorial: Time to adapt. Nature 464: 1245-1246.
38. McShane, L.M. et al 2005. Reporting recommendations for tumor MARKer prognostic studies (REMARK). Br. J. Cancer 93: 387-391.
39. Schilsky, R.L. 2010. Personalized medicine in oncology: the future is now. Nat. Rev. Drug Discov. 9: 363-366.
40. Tan, D.S. et al 2010. Anti-cancer drug resistance; understanding the mechanisms through the use of integrative genomics and functional RNA interference. Eur. J. Cancer 46: 2166-2177.
41. Bernards, R. 2010. It's diagnostics, stupid. Cell 141: 13-17.
42. Hudson, T.J. et al 2010. International network of cancer genome projects. Nature 464: 993-998.
43. Sharma, S.V. et al 2010. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141: 69-80.
44. Bean, J. et al 2007. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl. Acad. Sci. USA 104: 20932-20937.
45. Turke, A.B. et al 2010. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17: 77-88.
46. Farabegoli, F. et al 2001. Clone heterogeneity in diploid and aneuploid breast carcinomas as detected by FISH. Cytometry 46: 50-56.
47. Kronenwett, U. et al 2004. Improved grading of breast adenocarcinomas based on genomic instability. Cancer Res. 64: 904-909.
48. Lingle, W.L. et al 2002. Centrosome amplification drives chromosomal instability in breast tumor development. Proc. Natl. Acad. Sci. USA 99: 1978-1983.
49. Sotillo, R. et al 2010. Mad2-induced chromosome instability leads to lung tumor relapse after oncogene withdrawal. Nature 464: 436-440.
50. Teschendorff, A.E. & C. Caldas 2009. The breast cancer somatic 'muta-ome': tackling the complexity. Breast Cancer Res. 11: 301-305.
51. Wood, L.D. et al 2007. The genomic landscapes of human breast and colorectal cancers. Science 318: 1108-1113.